Sign Up Today and Learn More About Vico Therapeutics Stock
Invest in or calculate the value of your shares in Vico Therapeutics or other pre-IPO companies through EquityZen's platform.
Vico Therapeutics Stock (VICT)
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
About Vico Therapeutics Stock
Founded
2019
Industries
Software, Artificial Intelligence, Data and Analytics
Vico Therapeutics Press Mentions
Stay in the know about the latest news on Vico Therapeutics
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial
clinicaltrialsarena • Feb 26, 2026
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
businesswire • Feb 25, 2026
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
biospace • Feb 25, 2026
Vico Therapeutics Announces Patient Dosing in Twice-Annua...
pharmiweb • Feb 24, 2026
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
businesswire • Dec 03, 2025
Vico Therapeutics Management
Leadership team at Vico Therapeutics
Co-Founder
Gail Mandel
Co-Founder, Managing Director, and CSO
Judith van Deutekom
Join now and verify your accreditation status to gain access to:
- Vico Therapeutics Current Valuation
- Vico Therapeutics Stock Price
- Vico Therapeutics Management
- Available deals in Vico Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Vico Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Vico Therapeutics Revenue and Financials
- Vico Therapeutics Highlights
- Vico Therapeutics Business Model
- Vico Therapeutics Risk Factors
- Vico Therapeutics Research Report from SACRA Research
Trading Vico Therapeutics Stock
How to invest in Vico Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Vico Therapeutics through EquityZen funds. These investments are made available by existing Vico Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Vico Therapeutics stock?
Shareholders can sell their Vico Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
